GlassScriptPhysician profile
Drew A Jones
NPI 1902875297
$1,786.59
in general payments reported to CMS, 2019-2025
25 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $35.70 · 2021: $79.09 · 2022: $137 · 2023: $319 · 2024: $442 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $272.75 | 2019-2025 | |
| Irras USA, INC. | $179.85 | 2019 | |
| Pfizer INC. | $162.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $160.92 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $142.55 | 2023-2025 | Ilumya |
| Ucb, INC. | $120.26 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $112.57 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $99.39 | 2020-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $70.49 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $67.52 | 2019-2024 | Tremfya |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $66.10 | 2019 | |
| Arcutis Biotherapeutics, INC. | $49.55 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.01 | 2019-2025 | Cabtreo |
| Genzyme Corporation | $36.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.73 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $28.14 | 2024 | |
| Incyte Corporation | $26.61 | 2024 | Opzelura |
| Biofrontera INC. | $18.05 | 2021 | |
| Dermira, INC. | $16.75 | 2019 | |
| Kyowa Kirin, INC. | $15.60 | 2023 | Poteligeo |
| Verrica Pharmaceuticals INC. | $15.02 | 2024 | Ycanth |
| Almirall LLC | $14.77 | 2023 | Klisyri |
| Celgene Corporation | $14.65 | 2019 | |
| Lilly USA, LLC | $13.13 | 2022 | |
| Taro Pharmaceuticals USA, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.